Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Ashish Tiwari

Gastroenterology Eagan, MN Medical Doctor

NPI 1104119171 CMS profile 622274

1185 Town Centre Dr Ste 205, Eagan, MN 55123

Open in the dashboard

General payments

$3,649

279 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Ashish Tiwari of Eagan, MN is reported in the CMS Open Payments database as having received $3,649 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $209 13
2021 General $1,181 89
2020 General $910 74
2019 General $1,349 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashish Tiwari
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ashish Tiwari were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ashish Tiwari Gastroenterology median Middle half National median
2019 $1,349 $417 $126–$1,100 $163
2020 $910 $224 $74–$624 $114
2021 $1,181 $352 $106–$1,054 $132
2022 $209 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $1,130 102 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $690 57 payments
  3. Gilead Sciences, Inc. $421 22 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $288 24 payments
  5. Janssen Biotech, Inc. $278 19 payments
  6. Pfizer Inc. $138 8 payments
  7. Daiichi Sankyo Inc. $92 6 payments
  8. Ironwood Pharmaceuticals, Inc $76 6 payments
  9. Intercept Pharmaceuticals, Inc. $75 5 payments
  10. Merck Sharp & Dohme Corporation $67 5 payments
  11. Other $394 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,588 274 payments
  2. Education $61 5 payments
Products named General payments · program years 2019–2022
  1. XIFAXAN $600 51 payments
  2. HUMIRA $548 55 payments
  3. STELARA $278 19 payments
  4. MAVYRET $251 23 payments
  5. CREON $243 17 payments
  6. LINZESS $139 10 payments
  7. XELJANZ $138 8 payments
  8. TRULANCE $84 5 payments
  9. Entyvio Lower GI $72 5 payments
  10. ENTYVIO Internal Medicine $68 5 payments
  11. Other $1,075 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

243

Median for Gastroenterology: 569

Drug cost

$59,844

Median for Gastroenterology: $104,976

Branded share of claims

30.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 12 $26,320
Linzess Linaclotide Brand 19 $25,059
Movantik Naloxegol Oxalate Brand 12 $4,470
Cholestyramine Cholestyramine (With Sugar) Brand 19 $1,262
Omeprazole Generic 82 $1,155
Pantoprazole Sodium Generic 23 $396
Famotidine Generic 36 $379
Dicyclomine Hcl Generic 15 $295
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 13 $279
Sucralfate Generic 12 $229

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$80,437

Medicare's payments for the services billed

Medicare patients

254

Average age 71

Services billed

2,629

132 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 44%
Depression 30%
Ischemic heart disease 26%
Diabetes 22%
Chronic kidney disease 20%
Osteoporosis 20%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record